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Abstract The signalling pathways by which insulin triggers
protein synthesis were studied using an antisense strategy to
deplete ERK1/ERK2 and rapamycin to inhibit the p70S6K
pathway. The results indicated that ERK1/ERK2 principally
regulated the amount of the protein synthesis machinery
available in the cell while the p70S6K pathway contributed to
modulating its activation in response to insulin. ERK1/ERK2
also mediated in a small proportion of insulin-stimulated protein
synthesis which included the induction of c-fos protein. When c-
fos induction was blocked the majority of insulin-stimulated
protein synthesis still occurred and thus did not require
transcriptional regulation of c-fos or its targets.
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1. Introduction
One of the principal responses to insulin is the stimulation
of protein synthesis, resulting from increases in transcription
and translation [1,2]. Insulin both stimulates overall protein
synthesis and causes disproportionate increases in the expres-
sion of speci¢c proteins, e.g. the immediate early genes such as
c-fos. Regulation of protein synthesis is thus complex and it is
important to determine the pathways by which insulin trans-
duces its e¡ect on this process.
Insulin activates a number of signalling pathways including
the ERK1/ERK2 (extracellular regulated kinase 1 and 2) and
p70S6K pathways. ERK1/ERK2, also called p44 and p42 MAP
kinase, phosphorylate a number of transcription factors in
vitro and may be on the pathway responsible for the phos-
phorylation of the initiation factor eIF4E. Targets for the
p70S6K pathway may include the ribosomal proteins S6 and
S17, the elongation factor eEF-2 and the repressor 4E-BP1
[2^6]. Thus the ERK1/ERK2 and the p70S6K signalling path-
ways may mediate in the regulation of protein synthesis by
insulin [2,7^9].
To test the precise roles of ERK1/ERK2 in vivo we have
developed an antisense strategy which speci¢cally depletes
cells of ERK1/ERK2 [5,10,11]. Using the phosphorothioate
antisense probe, EAS1, we have demonstrated that ERK1/
ERK2 are absolutely required for the di¡erentiation of 3T3
¢broblasts to adipocytes, for insulin or serum stimulation of
DNA synthesis and for insulin-dependent activation of p90S6K
[10].
Using antisense elimination of ERK1/ERK2 we now test
the role of ERK1/ERK2 in the regulation of protein synthesis.
Additionally, we have related the ability of insulin to stimu-
late protein synthesis in the presence and absence of ERK1/
ERK2 knockout to the levels or control of speci¢c transcrip-
tional and translational regulators. The role of the p70S6K
pathway in mediating in insulin-stimulated protein synthesis
was tested using the inhibitor rapamycin [12].
2. Materials and methods
2.1. Cells and oligonucleotide treatment
3T3-L1 ¢broblasts were the kind gift of Dr G. Gould, University of
Glasgow, UK, and were used after di¡erentiation into 3T3-L1 adipo-
cytes as described previously [10]. 3T3-L1 adipocytes in serum-free
Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 0.125^
0.25% bovine serum albumin (BSA) were treated with oligonucleoti-
des (10 WM) for a total of 72 h in the presence of lipofectin for the
¢rst 8 h as described previously [10]. All oligonucleotides were
phosphorothioate modi¢ed. EAS1 and the corresponding sense and
random (scrambled) oligonucleotide sequences were as described pre-
viously [10]. The mismatch sequence (MM2) was 5P-GCAGCC-
GACGCAGCCCT-3P.
2.2. [3H]Leucine incorporation into protein
3T3-L1 adipocytes were incubated in the presence or absence of
100 nM insulin during the ¢nal 2 h or 24 h of the oligonucleotide
treatment, then washed three times with leucine-free DMEM and
incubated in DMEM containing 50 WM [3H]leucine (ICN, 1^2 WCi/
22 mm dish, 0.5 ml DMEM) for 1 h at 37‡C with or without insulin as
appropriate. The incubation was terminated by rapidly washing the
cells with excess ice-cold phosphate bu¡ered saline. The cells were
extracted by scraping into 140 Wl of 62.5 mM Tris-HCl (pH 7.4)
containing 1% SDS and homogenised by repeated expulsion through
a 25 gauge needle. Triplicate 25 Wl aliquots were precipitated in 1 ml
10% trichloroacetic acid (TCA) in the presence of 100 Wg BSA carrier.
After 1^2 h at 0‡C, the precipitates were diluted to 5 ml and collected
onto GF/C ¢lters. The ¢lters were extensively washed with ice-cold
10% TCA, air-dried, and counted in 3 ml Optiphase Hi-Safe scintil-
lant (Fisons Chemicals). Further extract aliquots were taken for meas-
urement of protein and assay of ERK1/ERK2 by Western blotting.
Non-speci¢c uptake was determined by exposure of cells to
[3H]leucine for 1 min at 37‡C prior to washing and extraction. These
values were subtracted from total values.
2.3. Laser scanning confocal microscopy of 3T3-L1 adipocytes
3T3-L1 adipocytes grown on glass coverslips in 22 mm dishes were
treated with oligonucleotide as above for 72 h, and then incubated in
the continued presence of oligonucleotides as given in the ¢gure
legends. Cells were then rapidly washed with ice-cold phosphate-bu¡-
ered saline and ¢xed in 70% (v/v) acetone/30% methanol (320‡C,
10 min) before being air-dried and stored at 320‡C prior to incuba-
tion with appropriate antibodies. Coverslips were incubated overnight
at 4‡C with 0.2 Wg/ml anti-c-fos antibody (Santa Cruz) in phosphate-
bu¡ered salts Dulbecco’s formula modi¢ed medium (ICN), washed
repeatedly with the same bu¡er and then incubated for 1 h at 4‡C
with 1:500 dilution of sheep anti-rabbit FITC conjugate antibody
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(Sera Lab) in the same bu¡er. Following further washes in the same
bu¡er the coverslips were mounted in 60% (v/v) glycerol/2.5% 1,4-
diazanicyclo-[2,2,2]octane and the slides examined using a Bio-Rad
MRC-600 Imaging System equipped with a krypton-argon laser (pro-
ducing excitation wavelengths at 488 nm, 567 nm and 648 nm) and a
Nikon oil immersion lens (magni¢cation U60). Images were produced
using COMOS software (Bio-Rad).
2.4. 2-Deoxyglucose transport assay
Cells in 22 mm dishes were washed three times with 1 ml of pre-
warmed Krebs Ringer HEPES bu¡er (136 mM NaCl, 4.7 mM KCl,
1.25 mM CaCl2, 1.25 mM MgSO4, 10 mM HEPES, pH 7.4), prein-
cubated for 10 min at 37‡C in 990 Wl of the same bu¡er and then
incubated in the presence or absence of 100 nM insulin for 30 min at
37‡C. 50 Wl of 2-deoxy-D-[3H]glucose (ICN, 1 WCi per well, 50 WM
¢nal concentration) was added and incubation continued for 4 min at
37‡C. Cells were washed and extracted as described above. Duplicate
30 Wl aliquots of the extract were counted in Optiphase Hi-Safe 3
scintillant. Further aliquots were taken for determination of protein
concentration and for analysis of ERK1/ERK2 by Western blotting.
Non-carrier mediated uptake was measured for each condition by
adding 25 WM cytochalasin B or ethanol 5 min prior to the insulin
stimulation and the counts incorporated (typically 6 10% of total
uptake in the absence of cytochalasin B) subtracted from the total
values.
2.5. Western blotting and other assays
Western blotting was performed as detailed in Sale et al. [10]. ERK
gel shift assays were performed as described in Arnott et al. [5].
Quanti¢cation was achieved by using an Epson scanner and Phoretix
software. Where appropriate, ERK levels are expressed as % of that in
lipofectin-only controls. 32P labelling of 4E-BP1 was undertaken as
described previously [5].
3. Results and discussion
Treatment of 3T3-L1 adipocytes with the antisense probe
EAS1 routinely eliminated ERK2 by s 93% and ERK1 to
levels undetected (e.g. Figs. 1 and 2). Figs. 1 and 2 show
the e¡ect of such depletion of ERK1/ERK2 on protein syn-
thesis, as measured by 3[H]leucine incorporation into protein
in cells incubated with or without insulin for 2 h or 24 h.
Removal of ERK1/ERK2 by EAS1 markedly decreased the
rate of protein synthesis in the presence of insulin. However,
EAS1 treatment also markedly decreased the basal rate of
protein synthesis. Thus the net e¡ect of EAS1 was to leave
the fold stimulation of protein synthesis by insulin largely
unaltered in both the shorter- and longer-term insulin stimu-
lation. Control sense or random oligonucleotides had no e¡ect
on the expression of ERK1/ERK2, rates of protein synthesis
in the presence or absence of insulin or the fold stimulation of
protein synthesis by insulin. EAS1 inhibition of basal protein
synthesis is consistent with the fact that serum-starved 3T3-L1
adipocytes contain active ERK1/ERK2 (V20% of the maxi-
mum insulin-stimulated activity) [13].
By contrast rapamycin, the p70S6K pathway inhibitor, had
no e¡ect on the basal rate of protein synthesis but reduced the
fold e¡ect of insulin stimulation in cells incubated for 24 h
with the hormone (see Fig. 2).
Taken together these results suggest that ERK1/ERK2 play
an important role in regulating the level of the protein syn-
thesis machinery available in the cell while the p70S6K path-
way contributes to modulating the activation of this machi-
nery in response to insulin. At the concentration used
rapamycin completely inhibits p70S6K in 3T3-L1 adipocytes
[12], yet the stimulation of protein synthesis by insulin was
incompletely inhibited either in the presence or in the absence
of EAS1 (Fig. 2). Moreover, rapamycin had little e¡ect on the
rate of protein synthesis in 3T3-L1 adipocytes stimulated with
insulin for only 2 h (11 þ 5% inhibition) and again did not
alter the basal (data not shown). These results suggest that
the p70S6K pathway is not the only pathway which mediates in
signalling insulin-stimulated protein synthesis and that anoth-
er pathway, for which the protein kinase B pathway is a
candidate, is involved [14].
The mechanism by which ERKs regulate the level of pro-
tein synthesis machinery is unknown. Potential sites of action
include the control of the cellular levels of key ribosomal
proteins, initiation factors or elongation factors (e.g. riboso-
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Fig. 1. Rates of protein synthesis in 3T3-L1 adipocytes incubated
with or without insulin for 2 h. Cells were incubated with oligonu-
cleotide and the transfection agent lipofectin as indicated. Rates of
protein synthesis are expressed as % of insulin-stimulated lipofectin
control. Results are means þ S.E.M. for at least three independent
experiments. Western blots of ERK1 and ERK2 from a representa-
tive experiment are also shown; for each condition there are a pair
of lanes. The left of each pair was obtained with cells incubated in
the absence of insulin. The right of each pair was obtained with
cells incubated in the presence of insulin. EAS1, antisense oligonu-
cleotide; S, sense oligonucleotide; R, random oligonucleotide.
Fig. 2. Rates of protein synthesis in 3T3-L1 adipocytes incubated
with or without insulin for 24 h. Cells were incubated with oligonu-
cleotide, rapamycin and the transfection agent lipofectin as indi-
cated. Rates of protein synthesis are expressed as % of insulin-
stimulated lipofectin control. Results are means þ S.E.M. for at least
three independent experiments. Western blots of ERK1 and ERK2
from a representative experiment obtained with cells incubated in
the presence of insulin are also shown. Similar Western blots of
ERK1 and ERK2 were obtained with cells incubated in the absence
of insulin. EAS1, antisense oligonucleotide; S, sense oligonucleotide;
R, random oligonucleotide; Rp, Rapamycin.
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Fig. 3. A: EAS1 prevents the induction of c-fos in response to insulin or serum in 3T3-L1 adipocytes. Cells were treated with no agent (i^iii),
lipofectin only (iv^vi) or antisense EAS1 (vii^ix) as detailed in Section 2 and then incubated for 1 h with no further additions (i, iv, vii),
100 nM insulin (ii, v, viii) or 20% serum (iii, vi, ix). Cells were visualised by laser scanning confocal microscopy. B: Control oligonucleotides
do not prevent the induction of c-fos in response to insulin or serum in 3T3-L1 adipocytes. Cells were treated with mismatch MM2 (i, ii), ran-
dom (iii, iv), or sense (v, vi) oligonucleotides as detailed in Section 2 and then incubated for a further 1 h with 100 nM insulin (i, iii, v) or
20% serum (ii, iv, vi). Cells were visualised by laser scanning confocal microscopy.
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mal S6, eEF-2, eIF2B and eIF4E) possibly via transcriptional
regulation.
We extended our present study to test the e¡ect of EAS1
treatment on the induction of the transcription factor, c-fos
using confocal microscopy. Pretreatment of the cells with
EAS1 caused near total elimination of ERK1/ERK2 protein
from both the cytoplasmic and nuclear compartments as as-
sessed by confocal microscopy (data not shown). Such elimi-
nation completely abolished the induction of endogenous c-
fos protein in the nucleus in response to either insulin or
serum (Fig. 3). Because in the basal state c-fos was absent it
follows that the fold stimulation by insulin or serum was
dramatically reduced by EAS1. Identical treatment of the cells
with sense, random or a mismatch oligonucleotide, MM2, was
without e¡ect on the induction of c-fos protein (Fig. 3). These
results provide the ¢rst direct evidence that ERK1/ERK2 are
absolutely required for insulin or serum to induce endogenous
c-fos protein. In support of our results studies with cells trans-
fected with arti¢cial reporter gene constructs containing lucif-
erase or measuring c-fos mRNA levels have also indicated
that induction of c-fos is under the control of the ERK1/
ERK2 pathway [15,16]. Our observation that elimination of
ERK1/ERK2 blocks the insulin-stimulated induction of en-
dogenous c-fos protein while leaving the fold stimulation of
total protein synthesis by insulin largely unaltered indicates
that a small component of insulin-stimulated protein synthe-
sis, which includes c-fos, is mediated through ERK1/ERK2.
Moreover, under conditions when c-fos induction was blocked
by EAS1, the majority of insulin-stimulated protein synthesis
still occurred. Thus transcriptional regulation at the c-fos site
or of c-fos targets is not required for insulin to stimulate the
majority of protein synthesis.
Three major lines of evidence were obtained that the action
of antisense EAS1 in depleting ERK1/ERK2 was speci¢c.
Firstly, identical treatment with sense or random or mismatch
oligonucleotides, which did not deplete ERK1/ERK2, had no
e¡ect on the rate of protein synthesis in the presence or ab-
sence of insulin or on the ability of insulin or serum to induce
c-fos (Figs. 1^3). Secondly, EAS1 has no e¡ect on the expres-
sion of c-Raf-1, protein kinase C, the upstream activator
MEK and the other MAP kinase family members, p46 and
p54 JNK and p38 MAP kinase [10,17]. EAS1 was without
e¡ect on the steady-state expression of p90S6K or the phos-
photyrosyl protein phosphatase SHP-2 (levels in the presence
of EAS1 were 103 þ 1% of control levels). Thirdly, we also
show that EAS1-treated 3T3-L1 adipocytes displayed normal
insulin responses of (a) increased glucose transport and (b)
4E-BP1 phosphorylation, indicating that EAS1 has not per-
turbed in any way normal cell functions (Figs. 4 and 5).
Phosphorylation of 4E-BP1 appears to regulate translation
[2]. As the basal and insulin-stimulated phosphorylation of
4E-BP1 and the fold stimulation of the phosphorylation by
insulin were not signi¢cantly altered by removal of ERK1/
ERK2, these results also show that the decreased rates of
protein synthesis observed upon removal of ERK1/ERK2
are not mediated by the altered phosphorylation of 4E-BP1.
In summary, our results show that multiple pathways are
required to achieve full protein synthesis. These pathways in-
clude the ERK1/ERK2 pathway, the p70S6K pathway and at
least one other pathway since signi¢cant protein synthesis still
occurred after inhibiting the p70S6K and ERK1/ERK2 path-
ways together (Fig. 2). The ERK1/ERK2 pathway is required
for the induction of c-fos (present work) and perhaps the
phosphorylation of the cap-binding initiation factor 4E
(eIF4E) [18]. At least S6, the elongation factor eEF-2 and
the repressor 4E-BP1 may be on the p70S6K pathway [2^5].
The other pathway may involve PI 3-kinase, protein kinase B
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Fig. 4. Insulin-stimulated phosphorylation of 4E-BP1 in 3T3-L1 adi-
pocytes. Cells were incubated with oligonucleotides and 32Pi in the
presence or absence of insulin (100 nM) for the ¢nal 10 min as indi-
cated. Extracts were prepared and analysed according to Section 2.
A: Representative autoradiograph showing phosphorylation of 4E-
BP1. L and Q are the characteristic phosphorylated species of 4E-
BP1 with the lower mobility of Q due to greater phosphorylation.
B: Quantitation of ERK2 expression as analysed by Western blot.
Results are mean þ S.E.M. for three independent experiments.
EAS1, antisense oligonucleotide; S, sense oligonucleotide.
Fig. 5. Insulin-stimulated glucose uptake in 3T3-L1 adipocytes. Cells
were treated with EAS1 for 72 h at the concentrations shown, with
lipofectin present for the ¢rst 8 h, then incubated in the presence
(F) or absence (b) of insulin (100 nM) for 30 min and rates of
2-deoxy-D-[3H]glucose uptake determined. Treatment of cells with
control oligonucleotides did not a¡ect 2-deoxy-D-[3H]glucose up-
take; e.g. values in dpm/Wg/min at 4.5 WM oligonucleotide were 8.4,
11.7 and 7.8 in the absence of insulin and 44.9, 48.1 and 46.5 in the
presence of insulin in each case for sense, random and antisense+
sense, respectively. ERK2 expression was assayed by Western blot-
ting of cell extract aliquots and quanti¢ed by densitometric scanning
(R).
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and glycogen synthase kinase 3 for which the initiation factor
eIF2B, a regulator of peptide chain initiation, may be at least
one of its targets [14,19].
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